Fluconazole prophylaxis against fungal colonization and infection in preterm infants.
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Invasive fungal infection is associated with substantial morbidity and mortality in preterm infants. We evaluated the efficacy of prophylactic fluconazole in preventing fungal colonization and invasive infection in extremely-low-birth-weight infants. METHODS: We conducted a prospective, randomized, double-blind clinical trial over a 30-month period in 100 preterm infants with birth weights of less than 1000 g. The infants were randomly assigned during the first five days of life to receive either intravenous fluconazole or placebo for six weeks. We obtained weekly surveillance cultures from all patients. RESULTS: The 50 infants randomly assigned to fluconazole and the 50 control infants were similar in terms of birth weight, gestational age at birth, and base-line risk factors for fungal infection. During the six-week treatment period, fungal colonization was documented in 30 infants in the placebo group (60 percent) and 11 infants in the fluconazole group (22 percent; difference in risk, 0.38; 95 percent confidence interval, 0.18 to 0.56; P=0.002). Invasive fungal infection with positive growth of fungal isolates from the blood, urine, or cerebrospinal fluid developed in 10 infants in the placebo group (20 percent) and none of the infants in the fluconazole group (difference in risk, 0.20; 95 percent confidence interval, 0.04 to 0.36; P=0.008). The sensitivities of the fungal isolates to fluconazole did not change during the study, and no adverse effects of the fluconazole therapy were documented. CONCLUSIONS: Prophylactic administration of fluconazole during the first six weeks of life is effective in preventing fungal colonization and invasive fungal infection in infants with birth weights of less than 1000 g.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, antifungal prophylaxis is now routinely used for extremely premature newborns in some neonatal units and for patients with certain types of hematologic malignancies, dramatically reducing rates of candidemia in these populations (15,16).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [16]
In the citing paper
“The high incidence of candidemia among infants, as well as the significant difference by race in this age group, was noted in the study of Kao et al. (16) and is known to be an important public health problem in this population (17, 35, 42).”
In the citing paper
“reduced the rate of invasive can-didiasis from 20% to 0% ( ) [344].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [344]
In the citing paper
“Regarding the latter observation, it is noteworthy that the formation of biofilms on central venous catheters by Candida spp. is associated with nosocomial infections (121, 122).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [121]
In the citing paper
“C. parapsilosis is notorious for the ability to form biofilms on catheters and other implanted devices (26, 38, 56, 80, 121, 122, 129, 269), for nosocomial spread by hand carriage, and for persistence in the hospital environment (38, 80, 122, 129, 262).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [121]
Citations
Cites
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
Hennekens, C. H., Buring, J. E., & Mayrent, S. L. (1987) · Medical Entomology and Zoology · Cited by 2,319
Manual of Clinical Microbiology, 7th ed.
Balows, A. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00102-9 · Cited by 1,613
Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory
Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., & Engstrom, M. C. (2000) · Cancer · doi:10.1002/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v · Cited by 1,360
Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,174
Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Manual of clinical microbiology
Murray, P. R., Versalovic, J. A., & Jorgensen, J. H. (1999) · Cited by 880
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Stoll, B. J., Gordon, T., Korones, S. B., Shankaran, S., Tyson, J. E., Bauer, C. R., Fanaroff, A. A., Lemons, J. A., Donovan, E. F., Oh, W., et al. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70191-9 · Cited by 873
Slavin, M. A., Osborne, B., Adams, R., Levenstein, M. J., Schoch, H. G., Feldman, A. R., Meyers, J. D., & Bowden, R. A. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1545 · Cited by 820
Research works printed but not linked: 2
- Spicer AD, 1992, Med Microbiol Lett, 1, 284
- 10.1111/j.1574-6968.2000.tb08938.x · doi:10.1111/j.1574-6968.2000.tb08938.x · Paper page
Cited by
Items 101–200 of 518
Challenging issues in neonatal candidiasis
Kaufman, D. A. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.487799 · Cited by 66
Self-citationMaródi, L., & Johnston, R. B. (2007) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3282f1dde9 · Cited by 67
Greenberg, R. G., Benjamin, D. K., Gantz, M. G., Cotten, C. M., Stoll, B. J., Walsh, M. C., Sánchez, P. J., Shankaran, S., Das, A., Higgins, R. D., et al. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.01.053 · Cited by 70
Strategies to Prevent Invasive Candidal Infection in Extremely Preterm Infants
Kaufman, D. A., & Manzoni, P. (2010) · Clinics in Perinatology · doi:10.1016/j.clp.2010.06.003 · Cited by 65
“The first study was a prospective, randomized, double-blind singlecenter trial involving 100 high-risk preterm infants with birth weight less than 1000 g who requiredcentral venousaccessor endotracheal intubation.(7) Infantswere randomly assigned during the first 5 days of life to receive 3 mg/kg fluconazole intraveno…”
BackgroundMethodInfluentialSelf-citationRisk Factors for Invasive Candidiasis in Infants >1500 g Birth Weight
Lee, J. H., Hornik, C. P. V., Benjamin, D. K., Herring, A. H., Clark, R. H., Cohen‐Wolkowiez, M., & Smith, P. B. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182769603 · Cited by 74
“com | 225 of invasive candidiasis.(8,9) We attempted to identify risk factors that would place larger infants at higher risk for invasive candidiasis to better target antifungal prophylaxis.”
Strategies for prevention of neonatal invasive candidiasis
Kaufman, D. A. (2003) · Seminars in Perinatology · doi:10.1016/s0146-0005(03)00067-3 · Cited by 65
Self-citationNosocomial Infections in the Neonatal Intensive Care Unit
Polin, R. A., & Saiman, L. M. (2003) · NeoReviews · doi:10.1542/neo.4-3-e81 · Cited by 64
Safety of fluconazole in paediatrics: a systematic review
Egunsola, O., Adefurin, A., Fakis, A., Jacqz-Aigrain, É., Choonara, I., & Sammons, H. M. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1468-2 · Cited by 66
“Seven of the 14 RCTs were exclusively conducted in neonates (term and preterm) [17–23], while the remainder involved children across the paediatric age spectrum (birth–17 years) [24–31].”
BackgroundCandida bloodstream infection in neonates
Benjamin, D. K., Garges, H. P., & Steinbach, W. J. (2003) · Seminars in Perinatology · doi:10.1016/s0146-0005(03)00061-2 · Cited by 70
Prevention and Treatment of Candida Infections in Neonates
Chapman, R. L. (2007) · Seminars in Perinatology · doi:10.1053/j.semperi.2007.01.006 · Cited by 64
Candiduria: Evidence-based approach to management, are we there yet?
Alfouzan, W. A., & Dhar, R. (2017) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2017.04.005 · Cited by 79
Ilett, K. F., & Kristensen, J. H. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.4.745 · Cited by 63
“Although this is higher than the notional 10% limit of safety, it is only ∼ 12% of the intravenous dose (3 mg/kg/day) suggested for prophylaxis against fungal infection in premature newborn infants [116].”
BackgroundInfection prevention for extremely low birth weight infants in the NICU
Fleiss, N., Tarun, S., & Polin, R. A. (2022) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2022.101345 · Cited by 69
Demırel, G., Çelik, İ. H., Erdeve, Ö., Saygan, S., Dilmen, U., & Canpolat, F. E. (2013) · European Journal of Pediatrics · doi:10.1007/s00431-013-2041-4 · Cited by 62
Outcomes Following Candiduria in Extremely Low Birth Weight Infants
Wynn, J. L., Tan, S., Gantz, M. G., Das, A., Goldberg, R. N., Adams-Chapman, I., Stoll, B. J., Shankaran, S., Walsh, M. C., Auten, K. J., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir800 · Cited by 60
“The incidence in ELBW infants is 7%–8% [1–3], and neurodevelopmental impairment (NDI) is common among survivors [4].”
BackgroundArendrup, M. C., Fisher, B. T., & Zaoutis, T. E. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02909.x · Cited by 67
“Each of the randomized controlled trials showed a reduction in the prevalence of invasive candidiasis [112–114].”
BackgroundSteinbach, W. J. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.02.009 · Cited by 65
“Six weeks of fluconazole therapy resulted in a statistically significant reduction in the incidence of fungal colonization (22% versus 60%) and a decrease in the development of invasive fungal infection (0% versus 20%) [57].”
BackgroundParikh, T. B., Nanavati, R. N., Patankar, C. V., Rao, S. P., Bisure, K., Udani, R. H., & Mehta, P. R. (2007) · PubMed · Cited by 64
Kaufman, D. A., Cuff, A. L., Wamstad, J. B., Boyle, R. J., Gurka, M. J., Grossman, L. B., & Patrick, P. D. (2010) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2010.11.002 · Cited by 59
Self-citationClerihew, L., Austin, N. C., & McGuire, W. L. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003850.pub3 · Cited by 74
Pediatric Antifungal Utilization
Prasad, P. A., Coffin, S. E., Leckerman, K. H., Walsh, T. J., & Zaoutis, T. E. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31817eeee5 · Cited by 56
Reporting an outbreak of Candida pelliculosa fungemia in a neonatal intensive care unit
Lin, H., Lin, S.-P., Su, B.-H., Ho, M., Ho, C., Lee, C.-Y., Lin, M.-H., Hsieh, H.-Y., Lin, H.-C., Li, T., et al. (2012) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2012.07.013 · Cited by 56
Vascular catheter‐related complications in newborns
Wu, J., & Mu, D. (2010) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2010.01934.x · Cited by 56
Invasive Fungal Infections in Children
Dornbusch, H. J., Manzoni, P., Roilides, E., Walsh, T. J., & Groll, A. H. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181b076b1 · Cited by 61
Prevention and Treatment of Nosocomial Sepsis in the NICU
Clark, R. H., Powers, R. J., White, R. D., Bloom, B. T., Sánchez, P. J., & Benjamin, D. K. (2004) · Journal of Perinatology · doi:10.1038/sj.jp.7211125 · Cited by 68
“Prevention There are two studies evaluating antifungal prophylaxis.(128,129) There have been no trials examining presumptive therapy or comparing prophylaxis with presumptive therapy.”
BackgroundBharwani, S. K., & Dhanireddy, R. (2007) · Journal of Perinatology · doi:10.1038/sj.jp.7211878 · Cited by 55
Watt, K., Benjamin, D. K., Cheifetz, I. M., Moorthy, G., Wade, K. C., Smith, P. B., Brouwer, K. L. R., Capparelli, E. V., & Cohen‐Wolkowiez, M. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31825d3091 · Cited by 59
Invasive Fungal Infections in the ICU
Shoham, S., & Marwaha, S. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609355262 · Cited by 63
Bhat, M. A., Bhat, J. I., Kawoosa, M. S., Ahmad, S. M., & Ali, S. W. (2009) · Journal of Perinatology · doi:10.1038/jp.2009.72 · Cited by 60
Hu, H.-J., Zhang, G.-Q., Zhang, Q., Shakya, S., & Li, Z.-Y. (2017) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2016.06.001 · Cited by 54
Strategies for prevention of nosocomial sepsis in the neonatal intensive care unit
Saiman, L. M. (2006) · Current Opinion in Pediatrics · doi:10.1097/01.mop.0000193300.25141.c5 · Cited by 56
Prophylactic oral antifungal agents to prevent systemic candida infection in preterm infants
Austin, N. C., & Darlow, B. A. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003478.pub2 · Cited by 51
Apisarnthanarak, A., Holzmann-Pazgal, G., Hamvas, A., Olsen, M. A. A., & Fraser, V. J. (2004) · Infection Control and Hospital Epidemiology · doi:10.1086/502469 · Cited by 50
“28 There are several limitations to this study.”
BackgroundLestner, J. M., Smith, P. B., Cohen‐Wolkowiez, M., Benjamin, D. K., & Hope, W. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12025 · Cited by 50
“the utility of fluconazole for prevention of fungal infections in neonates where the schedule 40 of administration changes with increasing postnatal age [51, 52]).”
BackgroundAntifungal Agents in Neonates: Issues and Recommendations
Almirante, B., & Rodríguez-Pardo, D. (2007) · Pediatric Drugs · doi:10.2165/00148581-200709050-00004 · Cited by 56
Devlin, R. K. (2006) · Advances in Neonatal Care · doi:10.1016/j.adnc.2006.01.005 · Cited by 51
Update on antifungal agents for paediatric patients
Groll, A. H., & Tragiannidis, A. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03334.x · Cited by 52
“In low-birthweight infants, fluconazole has been shown to reduce Candida infections [49,50]; on the basis of these studies, fluconazole prophylaxis is a valid option for centres with a high frequency (>10%) of invasive Candida infections in premature infants of <1000 g birthweight or in the setting of a nosocomial out…”
BackgroundChow, B. D. W., Linden, J. R., & Bliss, J. M. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.74 · Cited by 61
Strategies for the Prevention of Neonatal Candidiasis
Leibovitz, E. (2012) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2012.01.004 · Cited by 48
Benjamin, D. K., Kaufman, D. A., Hope, W. W., Smith, P. B., Arrieta, A. C., Manzoni, P., Kovanda, L. L., Lademacher, C., Isaacson, B., Jednachowski, D., et al. (2018) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001996 · Cited by 46
Self-citationEffect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants
Autmizguine, J., Smith, P. B., Prather, K. O., Bendel, C. M., Natarajan, G., Bidegain, M., Kaufman, D. A., Burchfield, D. J., Ross, A., Pandit, P., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky353 · Cited by 53
Self-citationAntifungal prophylaxis with azole derivatives
Castagnola, E., Machetti, M., Bucci, B., & Viscoli, C. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00847.x · Cited by 46
“In a recent randomised double-blind placebo-controlled study, fluconazole administered at 3 mg ⁄ kg and administered according to an age-adapted schedule, reduced both fungal colonisation and invasive fungal infections in neonates weighing less than 1000 g, requiring a vascular access or endotracheal intubation [27].”
MethodMcGuire, W. L., Clerihew, L., & Austin, N. C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003850.pub2 · Cited by 50
Strategies to Prevent Bacterial and Fungal Infection in the Neonatal Intensive Care Unit
Garland, J. S., & Uhing, M. R. (2009) · Clinics in Perinatology · doi:10.1016/j.clp.2008.09.005 · Cited by 49
Perniola, R., Faneschi, M. L., Manso, E., Pizzolante, M., Rizzo, A., Damiani, A. S., & Longo, R. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0114-2 · Cited by 43
“ule: an intravenous dose of 3 mg/kg body weight every third day for the first 2 weeks, every other day during weeks 3 and 4, and daily during the next 2 weeks [8].”
BackgroundTurkova, A., Roilides, E., & Sharland, M. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328343614e · Cited by 45
Ganesan, K., Harigopal, S., Neal, T. J., & YOXALL, C. W. (2008) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/adc.2008.145359 · Cited by 42
Echinocandins — First-Choice or First-Line Therapy for Invasive Candidiasis?
Sobel, J. D., & Revankar, S. G. (2007) · New England Journal of Medicine · doi:10.1056/nejme078078 · Cited by 42
Steinbach, W. J., & Walsh, T. J. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.006 · Cited by 43
“Six weeks of fluconazole therapy resulted in a statistically significant reduction in the frequency of fungal colonization (22% versus 60%; P ¼ .002) and a decrease in the development of invasive fungal infection (0% versus 20%) [ 51 ].”
BackgroundAziz, M. S., Patel, A. L., Losavio, J., Iyengar, A., Berven, M., Schloemer, N. J., Jakubowicz, A., Mathai, T., & Mcauley, J. B. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181bf8eb1 · Cited by 40
“The dosing interval changed with increasing postmenstrual age due to enhanced drug clearance, with every 72 hour dosing during weeks 1 and 2, every 48 hour dosing during weeks 3 and 4, and every 24 hour dosing during weeks 5 and 6.(9) Fluconazole group 2 infants were admitted during January 1, 2006 to August 31, 2006.”
BackgroundChanging of bloodstream infections in a medical center neonatal intensive care unit
Chen, I., Chiu, N., Chi, H., Hsu, C.-H., Chang, J., Huang, D. T., & Huang, C. (2015) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2015.08.023 · Cited by 42
“broad-spectrum antibiotics, postnatal steroids, and mechanical ventilation.(16) This high-risk population could benefit greatly from effective prophylactic measures.”
BackgroundLactoferrin for prevention of neonatal infections
Manzoni, P., Mostert, M., & Stronati, M. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32834592e6 · Cited by 41
Kaufman, D. A. (2012) · Early Human Development · doi:10.1016/s0378-3782(12)70014-2 · Cited by 39
“Studies of both 3mg/kg dosing and twice a week administration of fluconazole prophylaxis have demonstrated no significant increase in minimum inhibitory concentration (MIC) among fungal strains causing colonisation or infection over 5-, 6-, and 11-year time periods in various NICUs [4,14,20,32].”
BackgroundInfluentialSelf-citationYeast Colonization and Drug Susceptibility Pattern in the Pediatric Patients With Neutropenia
Haddadi, P., Zareifar, S., Badiee, P., Alborzi, A., Mokhtari, M., Zomorodian, K., Pakshir, K., & Jafarian, H. (2014) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.11858 · Cited by 43
“The most commonly colonized sites in the present study were the oral cavity and rectum, which was in accordance to the findings of the other studies (6, 20).”
BackgroundResultInfluentialBarker, C. I. S., Germovsek, E., Hoare, R. L., Lestner, J. M., Lewis, J. E. A., & Standing, J. F. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.002 · Cited by 44
“48–72 h) are often used in clinical practice [83,84].”
MethodEuropean survey on the use of prophylactic fluconazole in neonatal intensive care units
Kaguelidou, F., Pandolfini, C., Manzoni, P., Choonara, I., Bonati, M. R., & Jacqz-Aigrain, É. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1565-8 · Cited by 37
Treatment and Prophylaxis of Invasive Candidiasis
Tripathi, N., Watt, K., & Benjamin, D. K. (2012) · Seminars in Perinatology · doi:10.1053/j.semperi.2012.06.003 · Cited by 41
Momper, J. D., Capparelli, E. V., Wade, K. C., Kantak, A. D., Dhanireddy, R., Cummings, J. J., Nedrelow, J. H., Hudak, M. L., Mundakel, G. T., Natarajan, G., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00963-16 · Cited by 37
“Another commonly used fluconazole regimen for the prophylaxis of invasive candidiasis is 3 mg/kg given twice weekly (2, 3).”
BackgroundJohnsson, H., & Ewald, U. (2004) · Acta Paediatrica · doi:10.1111/j.1651-2227.2004.tb02695.x · Cited by 41
“The majority of candidal infections in newborns occur in the smallest infants (4), and a high rate of candidal infection has been reported in infants with a birthweight of 1000 g (3, 5, 6), or 1500 g (7–11).”
BackgroundAdvances in the treatment of invasive neonatal candidiasis
Botero-Calderon, L., Benjamin, D. K., & Cohen‐Wolkowiez, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1031108 · Cited by 38
“The fluconazole safety profile in neonates was also evaluated in the first five efficacy RCTs previously mentioned.”
BackgroundResultInfluentialTrofa, D. P., Soghier, L. M., Long, C., Nosanchuk, J. D., Gácser, A., & Goldman, D. L. (2011) · Mycopathologia · doi:10.1007/s11046-011-9429-3 · Cited by 42
“It is the predominant fungal organism isolated in many neonatal intensive care units (NICUs) [4, 15].”
BackgroundSmith, P. B., Steinbach, W. J., & Benjamin, D. K. (2005) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2005.05.007 · Cited by 42
Systemic antifungal prophylaxis for very low birthweight infants: a systematic review
Clerihew, L., Austin, N. C., & McGuire, W. L. (2007) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/adc.2007.121962 · Cited by 35
Candidemia in the 21st Century
Chang, A., Neofytos, D., & Horn, D. (2008) · Future Microbiology · doi:10.2217/17460913.3.4.463 · Cited by 43
“Similarly, prophylaxis with fluconazole has been shown to be beneficial in high-risk surgical patients and low birth-weight infants [52,53].”
BackgroundOutbreak of Pichia kudriavzevii fungaemia in a neonatal intensive care unit
Nagarathnamma, T., Chunchanur, S. K., Rudramurthy, S. M., Vineetha, K. R., Ramamurthy, K., Jillwin, J., & Ambica, R. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000645 · Cited by 35
“Risk factors for the development of fugal sepsis in neonates include intrinsic factors such as the immaturity of the immune system and increased permeability of the skin/ mucousmembrane, and extrinsic factors such as central vascular access, parenteral nutrition, broad-spectrum antibiotics, postnatal steroids, mechani…”
BackgroundDermitzaki, N., Baltogianni, M. S., Tsekoura, E., & Giapros, V. I. (2024) · Pathogens · doi:10.3390/pathogens13080660 · Cited by 38
“The first randomized control trials (RCTs) regarding the efficacy of fluconazole prophylaxis in susceptible neonatal populations were published in 2001 and reported potentiated results regarding its utility in the prevention of colonization and invasive infections [91,92].”
BackgroundInfluentialVenkatesh, M. P., Pham, D., Fein, M., Kong, L., & Weisman, L. E. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01298-06 · Cited by 34
“A dose that varies from 3 to 6 mg/kg/dose intravenously or orally every 72 to 48 h has been used effectively for prophylaxis of Candida infections in very-low-birth-weight infants (4, 20, 22).”
MethodAntifungal therapy for neonatal candidiasis
Zaoutis, T. E., & Walsh, T. J. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3282f1bec9 · Cited by 35
Recommendations for the management of candidemia in children in Latin America
Santolaya, M. E., Telles, F. D. Q., Matute, T. A., Colombo, A. L., Zurita, J., Tiraboschi, I. N., Cortés, J. A., Thompson-Moya, L., Guzmán-Blanco, M., Sifuentes‐Osornio, J., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.05.010 · Cited by 38
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Fluconazole
Charoo, N. A., Cristofoletti, R., Graham, A., Lartey, P. A., Abrahamsson, B., Groot, D. W., Kopp, S., Langguth, P., Polli, J. E., Shah, V. P., et al. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24181 · Cited by 38
The Epidemiology of Invasive Candidiasis
Pfaller, M. A., & Diekema, D. J. (2014) · Candida and Candidiasis · doi:10.1128/9781555817176.ch29 · Cited by 33
Invasive Candida infections in the neonate
Smith, P. B., Steinbach, W. J., & Benjamin, D. K. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.007 · Cited by 36
Ramos, J. T., Villar, S., Bouza, E., Bergón-Sendín, E., Pérez‐Rivilla, A., Collados, C. T., Andreu, M., Reyes, C. S., Campos-Herrero, M. I., de Heredia, J. L., et al. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00496-17 · Cited by 32
“Fluconazole prophylaxis has been associated with a decrease in the incidence of IC in controlled trials in VLBW neonates (18).”
BackgroundInvasive Candida Infections in Neonates after Major Surgery: Current Evidence and New Directions
Rose, D. U. D., Santisi, A., Ronchetti, M. P., Martini, L., Serafini, L., Betta, P., Maino, M., Cavigioli, F., Cocchi, I., Pugni, L., et al. (2021) · Pathogens · doi:10.3390/pathogens10030319 · Cited by 38
Candida parapsilosis candidaemia in a neonatal unit over 7 years: a case series study
Miranda, L. D. N., Rodrigues, E. C. D. A., Costa, S. F., van der Heijden, I. M., Dantas, K. C., Lobo, R., Basso, M., Varkulja, G. F., Krebs, V. L. J., Gibelli, M. A. B. C., et al. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-000992 · Cited by 40
“control of exposure to broad-spectrum antimicrobials, and the use of antifungal prophylaxis, may have an impact in reducing the incidence of candidaemia.(35) 36 In contrast, implementation of intensive programmes to maximise compliance with hand hygiene, and adherence to current recommendations for placement and care…”
BackgroundInvasive fungal infections in newborns and current management strategies
Hundalani, S. G., & Pammi, M. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.811925 · Cited by 35
Transmission of Infectious Diseases Through Breast Milk and Breastfeeding
Lawrence, R. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0788-5.10013-6 · Cited by 46
Preventing nosocomial bloodstream infection in very low birth weight infants
Edwards, W. H. (2002) · Seminars in Neonatology · doi:10.1053/siny.2002.9125 · Cited by 32
Krinko (2007) · Robert-Koch-Institut (RKI) · doi:10.25646/157 · Cited by 33
PHARMACOKINETICS OF PROPHYLACTIC MICAFUNGIN IN VERY-LOW-BIRTH-WEIGHT INFANTS
Kawada, M., Fukuoka, N., Kondo, M., Okazaki, K., Kusaka, T., Kawada, K., & Itoh, S. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181a0cfd1 · Cited by 31
Probiotic Use and Prevalence of Candidemia and Candiduria in a PICU
Kumar, S., Singhi, S. C., Chakrabarti, A., Bansal, A., & Jayashree, M. (2013) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e31829f5d88 · Cited by 33
Neonatal candidiasis: Results of an 8 year study
Çelebi, S., HACIMUSTAFAOĞLU, M. K., Köksal, N., Özkan, H., Çetınkaya, M., & Ener, B. (2012) · Pediatrics International · doi:10.1111/j.1442-200x.2012.03574.x · Cited by 37
Antifungal pharmacotherapy for neonatal candidiasis
Bliss, J. M., Wellington, M. A., & Gigliotti, F. (2003) · Seminars in Perinatology · doi:10.1016/s0146-0005(03)00060-0 · Cited by 32
Fluconazole prophylaxis: can we eliminate invasive Candida infections in the neonatal ICU?
Kaufman, D. A. (2008) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3282f79c48 · Cited by 34
Self-citationAntifungal prophylaxis in neonates
Manzoni, P., Jacqz-Aigrain, É., Rizzollo, S., Franco, C., Stronati, M., Mostert, M., & Farina, D. (2011) · Early Human Development · doi:10.1016/j.earlhumdev.2011.01.013 · Cited by 30
Makhoul, I. R., Bental, Y. A., Weisbrod, M., Sujov, P. O., Lusky, A., & Reichman, B. (2007) · Journal of Hospital Infection · doi:10.1016/j.jhin.2006.12.004 · Cited by 30
Empiric guidelines for treatment of Candida infection in high-risk neonates
Procianoy, R. S., Enéas, M. V., & Silveira, R. C. (2006) · European Journal of Pediatrics · doi:10.1007/s00431-006-0088-1 · Cited by 30
“Recent studies have demonstrated that infants with a very low birth weight have a high prevalence of fungal sepsis and that prophylactic fluconazole is effective in preventing invasive fungal infection [2, 4–6].”
BackgroundCohen‐Wolkowiez, M., Moran, C., Benjamin, D. K., & Smith, P. B. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283321ccc · Cited by 35
Blyth, C. C., Barzi, F., Hale, K. A., & Isaacs, D. (2012) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2012.02543.x · Cited by 30
Lee, J. Y., Kim, H., Shin, S. H., Choi, C. W., Kim, E., Choi, E. H., Kim, B. I., & Choi, J.-H. (2016) · BMC Pediatrics · doi:10.1186/s12887-016-0605-y · Cited by 34
“Fluconazole has been shown to be very effective in preventing candidiasis in previous studies with high incidences of IFIs (13 % [6] and 20 % [5] in the fluconazole-untreated groups).”
ResultAntifungal Drugs for Invasive Candida Infections (ICI) in Neonates: Future Perspectives
Bersani, I., Piersigilli, F., Goffredo, B. M., Santisi, A., Cairoli, S., Ronchetti, M. P., & Auriti, C. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00375 · Cited by 31
Huang, Y., Su, L.-H., Wu, T.-L., & Lin, T. (2004) · Journal of Hospital Infection · doi:10.1016/j.jhin.2004.07.020 · Cited by 35
Review of Fluconazole Treatment and Prophylaxis for Invasive Candidiasis in Neonates
Hornik, C. D., Bondi, D. S., Greene, N. M., Cober, M. P., & John, B. M. (2021) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-26.2.115 · Cited by 32
Triazole Use in the Nursery: Fluconazole, Voriconazole, Posaconazole, and Ravuconazole
Watt, K., Manzoni, P., Cohen‐Wolkowiez, M., Rizzollo, S., Boano, E., Jacqz-Aigrain, É., & Benjamin, D. K. (2013) · Current Drug Metabolism · doi:10.2174/138920013804870583 · Cited by 34
“In a prospective, randomized double-blind trial over a 30-month period of 100 infants with birth weights < 1000 g, those infants who received fluconazole for 6 weeks had a decrease in fungal colonization (22% versus 60%) as well as a decrease in the development of invasive fungal infection compared to placebo (0% vers…”
BackgroundManzoni, P. (2007) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/01.mpg.0000302971.06115.15 · Cited by 30
Fluconazole for the Prevention of Fungal Infections: Get Ready, Get Set, Caution
Fanaroff, A. A. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2183 · Cited by 28
Clinical practice: Obstructive renal candidiasis in infancy
Bisht, V., & Voort, J. V. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1514-6 · Cited by 28
Leonart, L. P., Tonin, F. S., Ferreira, V. L., Penteado, S. T. D. S., Motta, F. D. A., & Pontarolo, R. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.02.039 · Cited by 30
Austin, N. C., & McGuire, W. L. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003850.pub4 · Cited by 32
Invasive candidiasis and candidaemia in neonates and children: update on current guidelines
Tragiannidis, A., Tsoulas, C., & Groll, A. H. (2014) · Mycoses · doi:10.1111/myc.12268 · Cited by 40
Metadata
- Authors
- Kaufman, D., Boyle, R., Hazen, K. C., Patrie, J. T., Robinson, M., & Donowitz, L. G.
- Affiliations
- University of Virginia (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-12-06
- Volume
- 345
- Issue
- 23
- Pages
- 1660-1666
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2016673581
- Cited by
- 523
- References
- 46
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 13 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 21 · 2018: 17 · 2017: 18 · 2016: 19 · 2015: 18 · 2014: 24 · 2013: 26 · 2012: 42
- FWCI
- 12.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and Maternal Infections
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- fluconazole, antifungal prophylaxis, preterm infants, extremely low birth weight infants, invasive fungal infections, fungal colonization
- MeSH terms
- Antifungal Agents, Bacterial Infections, Candida, Candida albicans, Candidiasis, Double-Blind Method, Humans, Infant, Newborn, Infant, Premature, Infant, Premature, Diseases, Infusions, Intravenous, Microbial Sensitivity Tests, Mycoses, Prospective Studies, Trichosporon, Colony Count, Microbial, Fluconazole, Infant, Very Low Birth Weight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.